U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07436429) titled 'Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction' on Feb. 22.
Brief Summary: Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the r...